Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carmen Rodríguez-Cueto

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|March 11, 2025
Development of Novel Neuroprotective Agents Targeting GPCR Using in Vitro AssaysMaría Gómez-Cañas, Carmen Rodríguez-Cueto, Javier Fernández-Ruiz, et al.
Frontiers in Neuroscience|September 29, 2016
Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative DisordersGemma Navarro, Paula Morales, Carmen Rodríguez-Cueto, et al.
Frontiers in Molecular Neuroscience|May 10, 2019
Endocannabinoid System in Spinocerebellar Ataxia Type-3 and Other Autosomal-Dominant Cerebellar Ataxias: Potential Role in Pathogenesis and Expected Relevance as Neuroprotective TargetsMaría Gómez-Ruiz, Carmen Rodríguez-Cueto, Eva Luna-Piñel, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 28, 2025
Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosisLaura García-Toscano, Carmen Rodríguez-Cueto, Anna Furiano, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|March 20, 2014
Endocannabinoid-hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxiasCarmen Rodríguez-Cueto, Cristina Benito, Julián Romero, et al.
Methods in Molecular Biology (Clifton, N.J.)|September 24, 2022
Endocannabinoid-Binding Receptors as Drug TargetsMaría Gómez-Cañas, Carmen Rodríguez-Cueto, Valentina Satta, et al.
British Journal of Pharmacology|July 2, 2013
Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxiasCarmen Rodríguez-Cueto, Cristina Benito, Javier Fernández-Ruiz, et al.
British Journal of Pharmacology|March 26, 2018
Targeting glial cannabinoid CB<sub>2</sub> receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosisFrancisco Espejo-Porras, Laura García-Toscano, Carmen Rodríguez-Cueto, et al.
Brain Pathology (Zurich, Switzerland)|May 13, 2021
Inactivation of the CB<sub>2</sub> receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosisCarmen Rodríguez-Cueto, Marta Gómez-Almería, Laura García Toscano, et al.
Disease Models & Mechanisms|January 11, 2017
Upregulation of CB<sub>2</sub> receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosisMaría Fernández-Trapero, Francisco Espejo-Porras, Carmen Rodríguez-Cueto, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Methods in Molecular Biology (Clifton, N.J.)|March 11, 2025
Development of Novel Neuroprotective Agents Targeting GPCR Using in Vitro AssaysMaría Gómez-Cañas, Carmen Rodríguez-Cueto, Javier Fernández-Ruiz, et al.
Frontiers in Neuroscience|September 29, 2016
Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative DisordersGemma Navarro, Paula Morales, Carmen Rodríguez-Cueto, et al.
Frontiers in Molecular Neuroscience|May 10, 2019
Endocannabinoid System in Spinocerebellar Ataxia Type-3 and Other Autosomal-Dominant Cerebellar Ataxias: Potential Role in Pathogenesis and Expected Relevance as Neuroprotective TargetsMaría Gómez-Ruiz, Carmen Rodríguez-Cueto, Eva Luna-Piñel, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 28, 2025
Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosisLaura García-Toscano, Carmen Rodríguez-Cueto, Anna Furiano, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|March 20, 2014
Endocannabinoid-hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxiasCarmen Rodríguez-Cueto, Cristina Benito, Julián Romero, et al.
Methods in Molecular Biology (Clifton, N.J.)|September 24, 2022
Endocannabinoid-Binding Receptors as Drug TargetsMaría Gómez-Cañas, Carmen Rodríguez-Cueto, Valentina Satta, et al.
British Journal of Pharmacology|July 2, 2013
Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxiasCarmen Rodríguez-Cueto, Cristina Benito, Javier Fernández-Ruiz, et al.
British Journal of Pharmacology|March 26, 2018
Targeting glial cannabinoid CB<sub>2</sub> receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosisFrancisco Espejo-Porras, Laura García-Toscano, Carmen Rodríguez-Cueto, et al.
Brain Pathology (Zurich, Switzerland)|May 13, 2021
Inactivation of the CB<sub>2</sub> receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosisCarmen Rodríguez-Cueto, Marta Gómez-Almería, Laura García Toscano, et al.
Disease Models & Mechanisms|January 11, 2017
Upregulation of CB<sub>2</sub> receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosisMaría Fernández-Trapero, Francisco Espejo-Porras, Carmen Rodríguez-Cueto, et al.
Pageof 3